Jasdave Chahal
Founder at Tiba Biotech LLC
Profile
Jasdave Chahal is a Chief Scientist and founder of Tiba Biotech LLC, which is founded in 2018.
He is currently a Venture Partner at incTANK Inc. Mr. Chahal received his undergraduate degree from the University of Ottawa in 2006 and his doctorate from Princeton University in 2012.
Jasdave Chahal active positions
| Companies | Position | Start |
|---|---|---|
Tiba Biotech LLC
 Tiba Biotech LLC BiotechnologyHealth Technology Tiba Biotech LLC is a company that specializes in advancing the RNA medicine field with an improved approach to nucleic acid delivery. The company is based in Cambridge, MA. The company has developed a fully biodegradable nanoparticle delivery platform for safer vaccines and therapeutics, as well as a computational RNA design for more potent gene expression. The company's goal is to achieve better patient outcomes through rational design, from gene to delivery method beyond vaccines. The company was founded in 2017 by Christian Mandl, Karl H. Ruping, Jasdave Chahal. Karl H. Ruping has been the CEO since 2017. | Founder | 2017-12-31 |
incTANK Inc
 incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Private Equity Investor | - |
Training of Jasdave Chahal
| University of Ottawa | Undergraduate Degree |
| Princeton University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
incTANK Inc
incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Finance |
Tiba Biotech LLC
Tiba Biotech LLC BiotechnologyHealth Technology Tiba Biotech LLC is a company that specializes in advancing the RNA medicine field with an improved approach to nucleic acid delivery. The company is based in Cambridge, MA. The company has developed a fully biodegradable nanoparticle delivery platform for safer vaccines and therapeutics, as well as a computational RNA design for more potent gene expression. The company's goal is to achieve better patient outcomes through rational design, from gene to delivery method beyond vaccines. The company was founded in 2017 by Christian Mandl, Karl H. Ruping, Jasdave Chahal. Karl H. Ruping has been the CEO since 2017. | Health Technology |
- Stock Market
- Insiders
- Jasdave Chahal
